论文部分内容阅读
系统性红斑狼疮(systemic lupus erythematosus,SLE)是一种由遗传、环境、免疫等多种因素参与引起的多器官、多系统损害的自身免疫性疾病,其发病机制复杂,临床表现多样,病情多呈进行性发展。对于SLE的治疗,传统上主要以糖皮质激素联合免疫抑制剂为主,严重者辅以细胞毒药物或生物调节剂,但总体疗效欠佳,且不良反应较大。近年来,大量的基础研究和临床试验表明,免疫因素在SLE发病机制中起主要作用,三氧化二砷(ATO)能有效缓解、控制SLE的症状,并且对ATO治疗SLE的作用机制也进行了许多深入的研究。该文拟从ATO的药效特性、临床应用、作用机制等方面对ATO治疗SLE的研究现况做一概述。
Systemic lupus erythematosus (SLE) is a kind of autoimmune disease which is caused by the involvement of many factors such as heredity, environment, immunity and so on. Its pathogenesis is complex, the clinical manifestation is diverse, the condition is more Progressive development. For the treatment of SLE, traditionally mainly glucocorticoid combined with immunosuppressive agents, combined with cytotoxic drugs or biological regulators in severe cases, but the overall poor efficacy, and adverse reactions. In recent years, a large number of basic research and clinical trials have shown that immune factors play a major role in the pathogenesis of SLE. Arsenic trioxide (ATO) can effectively relieve and control the symptoms of SLE, and many of the mechanisms of action of ATO in the treatment of SLE the study. This article intends to summarize the research status of SLE treated with ATO from aspects of pharmacodynamics, clinical application and mechanism of ATO.